Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.830
+0.030 (1.07%)
May 9, 2025, 10:43 AM - Market open
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
38.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GRCE News
- 4 weeks ago - Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 - GlobeNewsWire
- 2 months ago - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - GlobeNewsWire
- 2 months ago - Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga
- 3 months ago - Grace Therapeutics Announces Private Placement Financing of up to $30 Million - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH - GlobeNewsWire
- 4 months ago - Grace Therapeutics to Participate in Upcoming Investor Events January 2025 - GlobeNewsWire